Cancer specialist Taiho to market MSD's Zolinza in Japan
This article was originally published in Scrip
Executive Summary
MSD is tapping into Taiho Pharmaceutical's strong presence in the oncology sector in Japan through a deal for the promotion in this market of its first-in-class molecule Zolinza (vorinostat).